BMC Cancer

Table 1 Synergism studies between NVP-AEW541 and lapatinib

From: Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

Lapatinib [μM]
AEW541 [μM]	1	2	2.5	3	3.5
0.5	^a	^a	0.76	0.52	0.46
1	^a	0.58	0.51	0.44	0.42
1.5	0.96	0.59	0.58	0.51	0.49
2	0.46	0.42	0.46	0.49	0.52
3	0.69	0.57	0.56	0.68	0.64

^a fraction affected <0.2

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com